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NGF concentrations in human cerebral arteries
NGF (hg/g)
Artery Nunmber Meani (SEM)
Anterior cerebral (AC) 7 0-82 (0-19)
Internal carotid (IC) 7 0 78 (0 16)
Posterior cerebral (PC) 7 2 02 (0-53)
Superior cerebellar (SC) 7 2 14 (0 45)
Posterior communicating 6 1 87 (0*58)
P values were determined by student's t test.
AC v SC P < 0-02; IC v PC P < 0-04; IC v SC P < 0
Mean NGF concentration v age of subject r = - 0 8, P
ache, as in temporal arteritis, and also
reduce NGF synthesis, which is increased by
inflammation.' Modulation of NGF activity
may thus provide a new approach to prevent
and treat vascular headaches.
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Triphasic waves in serotonin syndrome
The serotonin syndrome was first described
in 1960 in depressed patients with delirium
due to monoamine oxidase inhibitors and t.-
tryptophan administration.' Symptoms of
the serotonin syndrome include mental
status changes, behavioural changes, myo-
clonus, rigidity, hyperreflexia, and auto-
nomic instability with low grade fevers,
diarrhoea, headache, tachycardia, and pupil-
lary dilatation.2 The serotonin syndrome has
been noted to occur with several sero-
tomimetic agents, particularly when multiple
agents are used.'
Psychiatry and pharmacology literature
has described the serotonin syndrome for
several years. As the use of serotonin reup-
take inhibitors has increased, cases have
begun to appear in the neurology litera-
ture-often associated with combination
regimens that include serotonin reuptake
inhibitors and dopaminergic agents. These
cases have been attributed to the sero-
tomimetic effects of dopamine and its ago-
nists. I describe a patient admitted for acute
confusion who met criteria for the serotonin
syndrome, responded well to supportive
care, and whose EEG showed prominent
triphasic wave activity.
A 76 year old man had a history of
Parkinson's disease, recurrent depression,
chronic constipation, and non-insulin
dependent diabetes mellitus. He had right
sided tremors, bradykinesia, hypophonia,
and significant gait instability with occa-
sional visual hallucinations. Due to his
depression and concerns regarding the use
of tricyclic antidepressants in a patient
already at risk for autonomic dysfunction, he
was started on 50 mg sertraline at bedtime.
He initially responded well, experiencing no
notable side effects. About three days before
admission, amantidine was added to his
drug regimen which already included sertra-
line and Sinemet. The patient was brought
to the emergency department by his wife
due to increasing confusion, diarrhoea, and
frequent falls that had begun a day earlier.
On examination, the patient had a low
grade fever, extreme rigidity in all limbs, agi-
tation, confusion, and ongoing visual hallu-
cinations. Over the next four hours he
developed multifocal and startle myoclonus.
He had not received any neuroleptic or
antibiotic drugs in more than six months.
Electrolytes, creatine kinase, liver func-
tions, a complete blood count, and ammonia
concentration were all normal. Blood cul-
tures and urinalysis were also unremarkable.
A 16 channel EEG was obtained and
showed pronounced triphasic wave activity
and diffuse slowing. Supportive care with
intravenous fluids and acetaminophen were
initiated and all outpatient medications were
stopped. Within 24 hours the patient's
myoclonus began to subside and in 48 hours
he had returned to baseline without any
sequelae. He continues to do well on
Sinemet alone for his Parkinson's disease.
Case reports of the serotonin syndrome
have noted EEG abnormalities-delta range
activity, slow waves, spike and waves, and
polyspike and waves but triphasic waves
have not previously been reported. 4 5 The
diagnosis of the serotonin syndrome in the
Parkinson's disease population is a difficult
one as many of the features of the serotonin
syndrome are present in Parkinson's disease
alone. A high level of suspicion for the sero-
tonin syndrome in patients with Parkinson's
disease taking serotonin reuptake inhibitors
is necessary to make the diagnosis.
Electroencephalography may play an impor-
tant part in the diagnosis of the serotonin
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Pseudoseizures or non-epileptic
seizures (NES); 15 synonyms
Medical jargon is often confusing, particu-
larly when the condition described falls
within the domain of two medical special-
ties. This confusion reaches its zenith with
those seizure disorders that do not have an
epileptic aetiology. There are at least 15 syn-
onyms for a condition that occurs in 10%' to
26%2 of adults investigated for refractory
seizures. This causes confusion for patients,
doctors, and researchers. The adoption of a
common term must be the rational way for-
ward, but which one to choose?
The label pseudoseizures is the most
commonly used. Its great weakness is that it
is not acceptable to patients as the label
implies that the seizures are not real. The
reality of the "fit" is seldom an issue. The
label pseudoepileptic seizures is both less
well known and pejorative. Labels that are
offensive to patients are counterproductive
and best avoided.
The aetiology of this disorder is currently
a matter for speculation. Terms that imply a
psychological causation are misleading.
Psychogenic seizures, hysterical seizures,
psychogenic attacks, and hysterical attacks
are all inappropriate for this reason.
A good descriptive label is non-epileptic
attacks but this is seldom used. Non-epilep-
tic attack disorder (NEAD) is rarely used
and is complicated. Functional seizures,
hysteroepilepsy, pseudoepilepsy, hysterical
epilepsy, pseudoepileptic attacks, and psy-
choseizures are the least commonly used
terms. These labels should all be aban-
doned.
This leaves the term nion-epileptic seizures
(NES) as the favoured candidate; it is non-
judgmental, often used, acceptable to
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Multiple sclerosis: longitudinal mea-
surement of interleukin-1 receptor
antagonist
Inflammatory activity in multiple sclerosis is
regulated by a network of proinflammatory
and antiinflammatory cytokines. Identifying
downregulatory cytokines opens new poten-
tial therapeutic options in multiple sclero-
sis.' 2The interleukin-l receptor antagonist
(11-lra) is the only known naturally occur-
ring specific antagonistic cytokine; Il-Ira
competes with Il-1 for receptor binding and
lacks agonist activity. Il-Ira has been impli-
cated in the pathogenesis of stroke and sev-
eral inflammatory diseases.' Human I1-lra is
available as a recombinant protein; the first
controlled study using Il-lra for therapy (in
200
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Time point (code number)
Gd-DTPA enhancing cranial MRI lesions
(white columns) and serum Il-lra
concentrations (black dots) measured
longitudinally during one year in patient 1 with
active rr-MS. There was a clinical relapse at
time point 9, which was treated with
intravenous methylprednisolone. Changes in
MRI activity tended to precede changes in
serum Il-lra concentrations by three to four
weeks (one time point, P < 0 05).
sepsis) was published recently.4 Its agonist,
I1-1/-the predominant Il-i isoform in
humans-is consistently expressed in acute
multiple sclerosis plaques.' It is conceivable,
but so far neither confirmed nor disproved,
that the natural specific antagonist Il-Ira is
involved in the counterregulation of inflam-
matory activity in multiple sclerosis. If this
were the case, Il-lra would be a novel candi-
date for immunomodulatory therapy in mul-
tiple sclerosis.
We conducted a pilot study of nine
patients with definite multiple sclerosis. The
patients were followed up for one year by
clinical examination (EDSS) and MRI every
three to four weeks (resulting in 14 time
points with code numbers 1 to 14), in paral-
lel to measuring I1-l1B and Il-Ira concentra-
tions in serum and CSF. Five patients with a
relapsing-remitting multiple sclerosis (two
men, three women; ages 27-34; duration of
disease one to three years), and four patients
with chronic progressive multiple sclerosis
(one man, three women; ages 40-59; dura-
tion of disease five to 28 years) were studied.
Cranial MRI (Siemens Magnetom 1-0
Tesla, Munchen, Germany) images were
obtained according to standard guidelines.
They were T2 and TI weighted, with and
without 0-1 mmol/kg Gd-DTPA enhance-
ment. Serum (n = 118) and CSF samples
(n = 33) were frozen within two hours of
collection and stored at -80°C. I1-l1B and
11-Ira were measured by commercially avail-
able enzyme linked immunosorbent assay
(ELISA) kits (R and D Systems,
Minneapolis, MN; sensitivity lpg/ml for I1-
1/3 and 20 pg/ml for Il-lra; intra-assay preci-
sion < 8 5%). The assays were performed in
a blinded fashion, one assay for each patient.
A clinical relapse was defined as an increase
by > 1-0 EDSS point. A relative MRI maxi-
mum was defined as a time point with
> 1 Gd enhancing lesion if preceded and fol-
lowed by less MRI activity. Serum Il-lra
concentrations were individually defined as
extreme (> 3 box lengths from upper
boundary) using individual box plots for
each patient (box length between 25th and
75th percentile) according to the SPSS pro-
cedure "Examine". The association between
changes in Il-Ira concentrations and MRI
activity was tested with the sign test
(increase or decrease of Il-Ira concentration
or number of active MRI lesions between
two time points).
Relative MRI maxima and clinical
relapses were only seen in the group of
patients with relapsing-remitting multiple
sclerosis, not in the one with chronic-pro-
gressive multiple sclerosis. I1-lp was not
detectable in serum (n = 118 samples) or
CSF (n = 33 samples). Il-lra could be
detected in all serum samples, but not in
CSF. Hence serum Il-lra concentrations
were subject to further analysis. The median
serum II-Ira concentrations varied interindi-
vidually (range 45-422 pg/ml), but were all
within the normal published range.5 In the
patient with the highest total number (64) of
Gd enhancing lesions (patient 1), an
increase or decrease of MRI activity was fol-
lowed by an increase or decrease of I1-lra
concentrations by three to four weeks (one
time point, P < 0-05 in sign test, figure).
Individually defined extreme Il-lra concen-
trations were only seen in patients with
relapsing-remitting multiple sclerosis. There
were four such extreme concentrations in
four different patients. Two of those coin-
cided with relative maxima of MRI activity,
and one with a clinical (spinal) relapse.
Smaller than extreme fluctuations of Il-
Ira were not specific for multiple sclerosis
activity, as they were also found in the group
of patients with chronic-progressive multiple
sclerosis without clinical or MRI activity in
the observation period. This is probably due
to the fact that Il-l and Il-ira are involved in
a wide range of inflammatory activities.' The
longitudinal design including monthly visits
proved to be essential for defining individual
extreme Il-Ira peaks. Because of the few
patients, a significant association could be
shown in only one patient. In her, the very
high disease load (demonstrated by MRI
activity) probably allowed us to detect this
association. We could not detect Il-Ira in
CSF, or I1-1,B in CSF or serum, probably
because the concentrations were below the
detection limit of our ELISA assays.
Because the biologically active concentration
of Il-Ira is at least one magnitude higher
than that of I1-1,3 Il-Ira may be more easily
detectable than Il-l.
In conclusion, we found that fluctuations
of Il-lra may be associated with multiple
sclerosis activity. The role of Il-Ira in multi-
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Pathophysiology of the intermediate
syndrome of organophosphorus poison-
ing
We report a patient with the intermediate
syndrome with results of repetitive nerve
stimulation studies and single fibre EMG.'
A hypothesis for the pathophysiology of the
intermediate syndrome is proposed.
A 28 year old previously healthy Asian
woman drank a bottle of Fenthion (probably
about 60 ml). She was admitted swiftly to
hospital and treated with gastric lavage and
intravenous atropine and a single dose of
pralidoxime. After three to four days she
developed respiratory weakness and was
unable to lift her head. On the fifth day her
vital capacity fell. Her facial muscles were
weak, as was shoulder abduction and hip
flexion. The distal muscles were normal.
She had normal reflexes and no sensory
deficit. She was intubated, respirated, and
atropine was continued.
Her muscle strength slowly improved and
she was weaned from the respirator and by
the 15th day she was neurologically normal.
Neurophysiological studies were carried out
on the 7th, 14th, and 18th days. She recov-
ered completely after three weeks. Results
from motor and sensory nerve conduction
studies on the median nerve on the 18th day
were normal.
Repetitive nerve stimulation of the ulnar
nerve were carried out at the wrist with
recording from the abductor digiti minimi.
On day 7 a single stimulus produced a
repetitive discharge but the second and sub-
sequent stimuli did not (figure). The repeti-
tive discharge was present at every stimulus
with rates at l/2s but not at 3/s. It was pre-
sent when the trial stimulus followed a few
seconds after tetanus at 20/s for five sec-
onds.
No decremental responses were seen at
rates up to 50/s; nor was a decrement pre-
sent after one minute of exercise or after 10
seconds of repetitive stimulation at 20/s or
50/s. Incremental responses were not seen.
Single fibre EMG from the clinically normal
extensor digitorum communis showed two
single fibre pairs with borderline jitter val-
ues; the mean consecutive difference
(MCD) was 59 and 63 jus (normal < 55 ps).
Frontalis muscle was examined on day 7
and showed increased jitter with blocking.
Of 17 fibre pairs, 12 had increased jitter and
seven of these had greater than 10% block-
ing (figure). As expected, blocking was only
seen in pairs with a considerably raised
MCD.
The intermediate syndrome follows the
acute cholinergic crisis of organophosphorus
poisoning and is seen in up to 20%-50% of
cases depending on the severity of poisoning
and duration, and on the type of organ-
ophosphorus compound.' It differs from
myasthenia gravis in that it is a constant
rather than progressive weakness, responds
adversely to neostigmine, and recovers
within 18 days. There are no associated
autoimmune phenomena. Decremental
responses to repetitive nerve stimulation
have been seen sometimes but usually it has
been the clinically unaffected peripheral
muscles that were studied.
We propose that down regulation of
acetylcholine receptors (AChRs) could
explain the syndrome and neurophysiologi-
cal findings. These receptors have a half life
of 10 days before undergoing endocytosis
and proteolysis within the muscle fibre.2
Regulation of the number of AChRs and
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